SCHEMBL6316610

SCHEMBL6316610

Cc1ccccc1C(=O)Nc1onc(-c2cccnc2)c1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
ALDH1A1 P00352 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TYK2 P29597 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
CSF1R P07333 1/20 0.44
LMNA P02545 2/20 0.43
TSHR P16473 1/20 0.43
POLB P06746 1/20 0.43
FLT3 P36888 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316571 0.88 TYK2 (0.53) HTTKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL6315883 0.87 SMN1; SMN2 (0.52) HTTKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL6318780 0.87 SMN1; SMN2 (0.54) HTTKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL27591518 0.87 HTT (0.50) HTTKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL6314663 0.85 CYP2C9 (0.46) KDM4EMAPTALDH1A1L3MBTL1NPC1
SCHEMBL6317627 0.83 NAMPT (0.52) KDM4EALDH1A1L3MBTL1GAAMEN1
SCHEMBL27610087 0.81 HTT (0.53) HTTKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL6318671 0.81 KDM4E (0.56) KDM4EMAPTALDH1A1L3MBTL1MEN1
SCHEMBL6322761 0.80 FLT3 (0.45) HTTKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL6318137 0.80 DYRK1A (0.50) KDM4EMAPTALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 HTT 2134/4885KDM4E 1382/4885MAPT 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.